Axis pays Skr75 million for alcoholism test:
This article was originally published in Clinica
Axis has bought the rights to Pharmacia and Upjohn's product line for the diagnosis of long-term high alcohol consumption for Skr75 million ($9.4 million). As a result, the Norwegian company claims it will be the world leader in the alcohol-related diagnosis market. The agreement gives Oslo-based Axis the products, patent rights and applications, brands and research projects, with effect from October 1 1998.
You may also be interested in...
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.